US74365N2027 - Common Stock
PROTAGENIC THERAPEUTICS INC
NASDAQ:PTIX (11/12/2024, 8:26:39 PM)
Premarket: 0.8001 +0 (+0.01%)0.8
+0.03 (+3.9%)
Protagenic Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in New York City, New York and currently employs 1 full-time employees. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). The company operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally.
PROTAGENIC THERAPEUTICS INC
149 Fifth Avenue, Suite 500
New York City NEW YORK 10010
P: 12129948200
CEO: Garo H. Armen
Employees: 1
Website: https://protagenic.com/
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Protagenic Therapeutics just reported results for the second quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Protagenic Therapeutics (NASDAQ:PTIX) just reported results for the second quar...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Protagenic Therapeutics (NASDAQ:PTIX) just reported results for the first quart...
Protagenic Therapeutics just reported results for the first quarter of 2024.
Here you can normally see the latest stock twits on PTIX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: